Ms. Amy Fix is responsible for regulatory strategy and interactions with regulatory agencies, including the U.S. Food and Drug Administration and the European Medicines Agency. Ms. Fix was previously Senior Vice President of Regulatory Affairs at Novavax (NYSE: NVAX), where she led the development of multiple late-stage vaccine programs, including a Phase 3 global maternal immunization clinical trial conducted in 11 countries and two Phase 3 older adult programs for RSV and influenza franchises. Prior to Novavax, Ms. Fix was Senior Director of Regulatory Affairs at Emergent BioSolutions Inc. (NYSE: EBS). Previously she served in regulatory affairs positions at Human Genome Sciences, Shire, MedImmune, Inc., and Baxter. Ms. Fix received a Bachelor of Science in Molecular Biology from the University of Virginia and an MBA from Johns Hopkins University.